Annual CFI
$117.61 M
+$303.80 M+163.17%
December 31, 2023
Summary
- As of February 25, 2025, SNDX annual cash flow from investing activities is $117.61 million, with the most recent change of +$303.80 million (+163.17%) on December 31, 2023.
- During the last 3 years, SNDX annual CFI has risen by +$260.14 million (+182.52%).
- SNDX annual CFI is now at all-time high.
Performance
SNDX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$86.85 M
+$25.10 M+40.64%
September 30, 2024
Summary
- As of February 25, 2025, SNDX quarterly cash flow from investing activities is $86.85 million, with the most recent change of +$25.10 million (+40.64%) on September 30, 2024.
- Over the past year, SNDX quarterly CFI has stayed the same.
- SNDX quarterly CFI is now at all-time high.
Performance
SNDX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$32.91 M
+$46.77 M+337.40%
September 30, 2024
Summary
- As of February 25, 2025, SNDX TTM cash flow from investing activities is $32.91 million, with the most recent change of +$46.77 million (+337.40%) on September 30, 2024.
- Over the past year, SNDX TTM CFI has stayed the same.
- SNDX TTM CFI is now -72.02% below its all-time high of $117.61 million, reached on December 31, 2023.
Performance
SNDX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
SNDX Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +163.2% | 0.0% | 0.0% |
| 3 y3 years | +182.5% | 0.0% | 0.0% |
| 5 y5 years | +128.8% | 0.0% | 0.0% |
SNDX Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +163.2% | at high | +163.1% | -72.0% | +117.7% |
| 5 y | 5-year | at high | +163.2% | at high | +163.1% | -72.0% | +117.7% |
| alltime | all time | at high | +163.2% | at high | +163.1% | -72.0% | +117.7% |
Syndax Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $86.85 M(+40.6%) | $32.91 M(-337.4%) |
| Jun 2024 | - | $61.75 M(-162.1%) | -$13.86 M(+713.0%) |
| Mar 2024 | - | -$99.40 M(+510.2%) | -$1.71 M(-101.4%) |
| Dec 2023 | $117.61 M(-163.2%) | -$16.29 M(-140.6%) | $117.61 M(-3253.1%) |
| Sep 2023 | - | $40.08 M(-45.8%) | -$3.73 M(-92.6%) |
| Jun 2023 | - | $73.91 M(+271.1%) | -$50.60 M(-71.0%) |
| Mar 2023 | - | $19.91 M(-114.5%) | -$174.46 M(-6.3%) |
| Dec 2022 | -$186.19 M(+355.5%) | -$137.63 M(+1926.0%) | -$186.19 M(+71.6%) |
| Sep 2022 | - | -$6.79 M(-86.4%) | -$108.52 M(+44.5%) |
| Jun 2022 | - | -$49.95 M(-710.5%) | -$75.09 M(+2068.4%) |
| Mar 2022 | - | $8.18 M(-113.6%) | -$3.46 M(-91.5%) |
| Dec 2021 | -$40.87 M(-71.3%) | -$59.96 M(-325.1%) | -$40.87 M(-9.3%) |
| Sep 2021 | - | $26.63 M(+22.8%) | -$45.06 M(-14.0%) |
| Jun 2021 | - | $21.68 M(-174.2%) | -$52.41 M(-65.7%) |
| Mar 2021 | - | -$29.23 M(-54.4%) | -$152.71 M(+7.1%) |
| Dec 2020 | -$142.53 M(-1215.2%) | -$64.14 M(-432.8%) | -$142.53 M(+98.5%) |
| Sep 2020 | - | $19.27 M(-124.5%) | -$71.79 M(-8.8%) |
| Jun 2020 | - | -$78.61 M(+312.6%) | -$78.70 M(+313.7%) |
| Mar 2020 | - | -$19.05 M(-388.9%) | -$19.02 M(-248.8%) |
| Dec 2019 | $12.78 M(-75.1%) | $6.60 M(-46.7%) | $12.78 M(-42.3%) |
| Sep 2019 | - | $12.36 M(-165.3%) | $22.15 M(+66.6%) |
| Jun 2019 | - | -$18.93 M(-248.5%) | $13.29 M(-74.2%) |
| Mar 2019 | - | $12.75 M(-20.1%) | $51.51 M(+0.2%) |
| Dec 2018 | $51.40 M | $15.96 M(+355.0%) | $51.40 M(+39.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $3.51 M(-81.8%) | $36.99 M(-8.4%) |
| Jun 2018 | - | $19.28 M(+52.5%) | $40.40 M(-361.6%) |
| Mar 2018 | - | $12.64 M(+715.7%) | -$15.44 M(-9.5%) |
| Dec 2017 | -$17.07 M(-6.6%) | $1.55 M(-77.6%) | -$17.07 M(-708.4%) |
| Sep 2017 | - | $6.92 M(-118.9%) | $2.81 M(-28.7%) |
| Jun 2017 | - | -$36.56 M(-431.9%) | $3.94 M(-90.1%) |
| Mar 2017 | - | $11.01 M(-48.6%) | $39.87 M(-318.1%) |
| Dec 2016 | -$18.28 M(-70.4%) | $21.43 M(+166.2%) | -$18.28 M(-68.1%) |
| Sep 2016 | - | $8.05 M(-1390.1%) | -$57.27 M(-21.3%) |
| Jun 2016 | - | -$624.00 K(-98.7%) | -$72.73 M(-18.6%) |
| Mar 2016 | - | -$47.14 M(+168.5%) | -$89.32 M(+44.8%) |
| Dec 2015 | -$61.67 M(-3366.4%) | -$17.56 M(+136.9%) | -$61.67 M(+33.5%) |
| Sep 2015 | - | -$7.41 M(-56.9%) | -$46.21 M(+19.1%) |
| Jun 2015 | - | -$17.21 M(-11.7%) | -$38.80 M(+103.7%) |
| Mar 2015 | - | -$19.48 M(+827.8%) | -$19.05 M(-1108.9%) |
| Dec 2014 | $1.89 M(-146.9%) | -$2.10 M(<-9900.0%) | $1.89 M(-3050.0%) |
| Sep 2014 | - | $0.00(-100.0%) | -$64.00 K(-11.1%) |
| Jun 2014 | - | $2.54 M(+74.7%) | -$72.00 K(-97.2%) |
| Mar 2014 | - | $1.45 M(-135.8%) | -$2.58 M(-36.1%) |
| Dec 2013 | -$4.03 M(-915.2%) | -$4.05 M(>+9900.0%) | -$4.03 M(<-9900.0%) |
| Sep 2013 | - | -$8000.00(-124.2%) | $25.00 K(-24.2%) |
| Jun 2013 | - | $33.00 K(>+9900.0%) | $33.00 K(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | $494.00 K | - | - |
FAQ
- What is Syndax Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals annual CFI year-on-year change?
- What is Syndax Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly CFI year-on-year change?
- What is Syndax Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals TTM CFI year-on-year change?
What is Syndax Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of SNDX is $117.61 M
What is the all time high annual CFI for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high annual cash flow from investing activities is $117.61 M
What is Syndax Pharmaceuticals annual CFI year-on-year change?
Over the past year, SNDX annual cash flow from investing activities has changed by +$303.80 M (+163.17%)
What is Syndax Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of SNDX is $86.85 M
What is the all time high quarterly CFI for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high quarterly cash flow from investing activities is $86.85 M
What is Syndax Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, SNDX quarterly cash flow from investing activities has changed by $0.00 (0.00%)
What is Syndax Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of SNDX is $32.91 M
What is the all time high TTM CFI for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high TTM cash flow from investing activities is $117.61 M
What is Syndax Pharmaceuticals TTM CFI year-on-year change?
Over the past year, SNDX TTM cash flow from investing activities has changed by $0.00 (0.00%)